Paratek Pharmaceuticals, Inc. (PRTK)
Stock Price:
$4.48 USD
-0.03 (-0.67%)
Updated Aug 6, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
193.23M |
| Revenue (ttm) |
22.87M |
| Net Income (ttm) |
-120.80M |
| Shares Out |
43.13M |
| EPS (ttm) |
-3.44 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 6, 2020 |
| Last Price |
$4.48 |
| Previous Close |
$4.51 |
| Change ($) |
-0.03 |
| Change (%) |
-0.67% |
| Day's Open |
4.52 |
| Day's Range |
4.45 - 4.64 |
| Day's Volume |
293,519 |
| 52-Week Range |
2.50 - 6.41 |
More Stats
| Market Cap |
193.23M |
| Enterprise Value |
260.70M |
| Earnings Date (est) |
Aug 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
43.13M |
| Float |
37.04M |
| EPS (basic) |
-3.49 |
| EPS (diluted) |
-3.44 |
| FCF / Share |
-3.10 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.94M |
| Short Ratio |
6.44 |
| Short % of Float |
8.97% |
| Beta |
1.52 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
8.45 |
| PB Ratio |
n/a |
| Revenue |
22.87M |
| Operating Income |
-105.89M |
| Net Income |
-120.80M |
| Free Cash Flow |
-129.10M |
| Net Cash |
-67.47M |
| Net Cash / Share |
-1.56 |
| Gross Margin |
-115.87% |
| Operating Margin |
-463.08% |
| Profit Margin |
-528.30% |
| FCF Margin |
-564.58% |
| ROA |
-26.15% |
| ROE |
-1,459.30% |
| ROIC |
-27.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
5 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$16.80*
(275.00% upside)
Low
6.00
Current: $4.48
High
34.00
Target: 16.80
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 16.54 | 17.12 | 12.62 | 0.03 | - | 4.34 | 0.48 | 11.03 | 19.69 | 12.50 |
| Revenue Growth | -3.35% | 35.68% | 43403.45% | - | - | 808.37% | -95.66% | -44.01% | 57.55% | - |
| Gross Profit | 13.06 | 17.12 | 12.62 | 0.03 | - | 4.34 | 0.48 | 9.60 | 19.69 | 12.50 |
| Operating Income | -116 | -104 | -85.16 | -110 | -73.61 | -7.80 | -7.54 | -11.86 | -3.76 | -9.22 |
| Net Income | -129 | -112 | -89.07 | -112 | -70.86 | -17.84 | -4.65 | -12.02 | -3.88 | -9.30 |
| Shares Outstanding | 32.79 | 31.51 | 26.83 | 20.25 | 16.50 | 2.53 | 0.06 | 1.42 | 1.13 | 1.12 |
| Earnings Per Share | -3.93 | -3.57 | -3.32 | -5.51 | -4.29 | -7.82 | -185.13 | -8.40 | -3.48 | -8.28 |
| Operating Cash Flow | -134 | -81.18 | -78.57 | -94.10 | -54.68 | -18.53 | -6.36 | -15.21 | -5.71 | -19.55 |
| Capital Expenditures | -0.24 | -0.06 | -1.12 | -0.69 | -0.86 | - | - | -0.04 | -0.06 | -0.07 |
| Free Cash Flow | -134 | -81.24 | -79.69 | -94.79 | -55.54 | -18.53 | -6.36 | -15.25 | -5.77 | -19.61 |
| Cash & Equivalents | 216 | 251 | 152 | 129 | 134 | 98.80 | 1.21 | 85.48 | 62.56 | 68.17 |
| Total Debt | 263 | 229 | 59.19 | 38.97 | 19.57 | - | 1.35 | - | - | - |
| Net Cash / Debt | -47.12 | 21.66 | 92.70 | 89.88 | 114 | 98.80 | -0.14 | 85.48 | 62.56 | 68.17 |
| Assets | 251 | 300 | 164 | 136 | 146 | 110 | 1.29 | 98.06 | 69.15 | 73.81 |
| Liabilities | 291 | 253 | 81.22 | 64.14 | 44.68 | 14.74 | 35.05 | 2.66 | 3.40 | 10.00 |
| Book Value | -39.65 | 47.58 | 82.48 | 71.59 | 101 | 95.22 | -114 | 95.39 | 65.75 | 63.81 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Paratek Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
101 |
| CEO |
Evan Loh |
Stock Information
| Ticker Symbol |
PRTK |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: PRTK |
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.